Phillips, R., Hancock, B., Graham, J., Bromham, N., Jin, H., & Berendse, S. (2012). Prevention and management of neutropenic sepsis in patients with cancer: Summary of NICE guidance. BMJ, 345, e5368.
The purpose of the article was to assess systemic reviews of best available evidence, including consideration of cost, management of neutropenic sepsis leading to avoidable deaths, and the lack of systems for urgent assessment and lack of institutional policies for managing neutropenic sepsis. Adults (aged 18 or older) with acute leukaemias, stem cell transplantations or solid tumors with expected neutropenia of 0.5 x 109/L or less post-chemotherapy were assessed.
This was an evidence-based guideline with a guideline summary process of development.
Inclusion criteria included adult patients receiving chemotherapy. Exclusion criteria included being younger than age 18 and a diagnosis of lymphoma.
The phase of care was active anti-tumor treatment
High-quality evidence based on systematic reviews/meta-analyses of randomized, controlled trials (RCTs), moderate quality evidence based on systematic reviews, experienced opinion of Guideline Development Group (GDG), and National Cancer Action Team referenced as experience and opinion sources. Low-level evidence includes observational studies.
High-quality evidence (systematic reviews/meta-analysies of RCTs):
Moderate quality evidence (systematic reviews):
Experienced opinion of Guideline Development Group (GDG):
Low level evidence (observational studies):
High-quality evidence exists for practice recommendations: